<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206931</url>
  </required_header>
  <id_info>
    <org_study_id>21002</org_study_id>
    <nct_id>NCT03206931</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion</brief_title>
  <official_title>Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      Selitrectinib expanded access is for minor and adult patients with cancer having a change in&#xD;
      a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an&#xD;
      ongoing selitrectinib clinical trial or have other considerations that prevent access to&#xD;
      selitrectinib through an existing clinical trial. Expanded access is intended to treat&#xD;
      individual patients with different types of cancers with a NTRK gene fusion, including blood&#xD;
      cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Solid Tumors Harboring NTRK Fusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selitrectinib (BAY2731954)</intervention_name>
    <description>Selitrectinib is administered as capsules or liquid formulation.</description>
    <other_name>Loxo-195</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion&#xD;
&#xD;
          -  Previous treatment with a kinase inhibitor with known activity on TRK inhibition&#xD;
&#xD;
          -  Unable to participate in an ongoing selitrectinib clinical trial&#xD;
&#xD;
          -  Medically suitable for treatment with selitrectinib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in an ongoing clinical study with a TRK inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Neurotrophic tyrosine receptor kinase (NTRK)</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>Fusion Positive</keyword>
  <keyword>Children</keyword>
  <keyword>Loxo-195</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selitrectinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

